Journal ArticleOPEN ACCESS

Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review

Clinical Case Reports (2019) 7(10) 1957-1961
DOI: 10.1002/ccr3.2257
5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Central nervous system (CNS)-relapsed mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non-Hodgkin lymphomas and may be considered as successful treatment for CNS-relapsed MCL in the future as well.

Author supplied keywords

Cite

CITATION STYLE

APA

Rich, J. D., Clark, S. M., Fedoriw, Y., Jewells, V., Wood, W., & Dittus, C. (2019). Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review. Clinical Case Reports, 7(10), 1957–1961. https://doi.org/10.1002/ccr3.2257

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free